These free open-world games offer vast and beautiful open worlds, great exploration, loads of content; there's almost no catch.

The final, formatted version of the article will be published soon. Purpose:To establish a dual-energy CT (DECT) based nomogram for predicting progression-free survival (PFS) in locally advanced ...

Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five-year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine ...

Abstract: This article presents a comprehensive physics-based model for back-end-of-line (BEOL)-compatible oxide-semiconductor-based ferroelectric field-effect transistors (FeFETs). The proposed model ...

Abstract: Multimodal survival analysis aims to combine heterogeneous data sources to improve the prediction quality of survival outcomes. However, this task is particularly challenging due to high ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic ...

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...

Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...